Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Nimble Therapeutics is a biotechnology company dedicated to transforming drug discovery through its proprietary platform for peptide synthesis, screening, and optimization. They focus on rapidly identifying and advancing novel peptide-based therapeutics against challenging disease targets that have been difficult to address with traditional drug modalities. Their approach combines massively parallel chemical synthesis with advanced screening and machine learning to accelerate the development of new medicines.
Primary center for research and development, high-throughput peptide synthesis and screening, computational biology, and corporate operations.
State-of-the-art laboratory facilities designed for advanced peptide chemistry, biological screening, and data analysis. Likely incorporates collaborative workspaces to foster innovation.
Nimble Therapeutics likely fosters a highly innovative, science-driven, and collaborative work environment. Employees are expected to be agile and contribute to a fast-paced drug discovery process, with a strong emphasis on teamwork and problem-solving.
The Madison headquarters is central to Nimble's operations, housing its core technology platform and the scientific expertise driving its drug discovery pipeline. Its location in a recognized biotech hub provides access to talent and research collaborations.
While Nimble Therapeutics's primary physical operations are centered in Madison, Wisconsin, its impact and collaborations are global. The company engages with international pharmaceutical partners, research institutions, and contract research organizations to advance its pipeline and leverage its platform technology worldwide. Their drug candidates are being developed for potential global markets.
630 W Washington Ave, Suite 300
Madison
Wisconsin
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Nimble Therapeutics' leadership includes:
Nimble Therapeutics has been backed by several prominent investors over the years, including:
Based on publicly available information, Nimble Therapeutics has maintained a relatively stable core executive team. No major high-profile executive hires or departures have been widely announced in the last 12-18 months, suggesting continuity in leadership.
Discover the tools Nimble Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Nimble Therapeutics likely utilizes a common corporate email format. The most probable pattern is the first initial followed by the last name.
[first_initial][last]@nimbletherapeutics.com
Format
jpatel@nimbletherapeutics.com
Example
80%
Success rate
Business Wire • October 19, 2023
Nimble Therapeutics and Incyte entered into an exclusive worldwide license and collaboration agreement for Nimble’s oral 3CL protease (Mpro) antagonist program, NHL-338, for SARS-CoV-2 and other coronaviruses. Nimble will receive an upfront payment and is eligible for development, regulatory, and commercial milestones, plus royalties....more
Nimble Therapeutics Press Release / Business Wire • October 16, 2023
Nimble Therapeutics presented preclinical data for its lead oral GLP-1/GIP/Glucagon tri-agonist candidate, NBL-015, at ObesityWeek® 2023. The data demonstrated significant weight loss, improved glycemic control, and favorable tolerability in preclinical models, supporting its potential as a best-in-class oral treatment for obesity and related metabolic diseases....more
Business Wire • February 7, 2023
Nimble Therapeutics announced the closing of a $50 million Series C financing round co-led by new investors Deerfield Management and Longitude Capital, with participation from existing investors GV, Catalio Capital Management, and Agent Capital. The funds will be used to advance its pipeline of novel peptide therapeutics and further develop its proprietary drug discovery platform....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Nimble Therapeutics, are just a search away.